Clinical Trial Update: A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating eribulin mesylate with avelumab in cisplatin-ineligible metastatic urothelial cell cancer; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Cancer

Drugs mentioned

• Avelumab (avelumab)
• ERIBULIN MESYLATE (Eribulin mesylate)

Snippet

Sponsor: Monika Joshi, MD | Conditions: Metastatic Urothelial Cell Cancer | Phase 1 | Status: TERMINATED | Results posted: 2020-07-09